Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025)
Benitec Biopharma (BNTC) reported Income from Continuing Operations of 28199988.0 for Q4 2025, up 99.73% on a YoY basis from 14119103.03 in Q4 2024, and up 99.84% sequentially from 17378369000.0 in Q3 2025.
Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Benitec Biopharma (BNTC) has 7 years of Income from Continuing Operations data on file, last reported at 28199988.0 in Q4 2025.
- For the quarter ending Q4 2025, Income from Continuing Operations rose 99.73% year-over-year to 28199988.0; the trailing twelve-month figure through Dec 2025 stood at 29592465988.0 (down 64.51% YoY), and the FY2025 full-year result was 7770149000.0, down 228.5% from the prior year.
- Income from Continuing Operations improved to 28199988.0 in Q4 2025, from 17378369000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3600000.0 in Q1 2022 to a low of 17378369000.0 in Q3 2025.
- A 5-year average of 2384157499.4 and a median of 13314000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations plunged 78152.51% in 2024 and soared 99.73% in 2025, its largest moves.
- Tracing BNTC's Income from Continuing Operations over 5 years: stood at 4987000.0 in 2021, then slipped by 27.07% to 6337000.0 in 2022, then plunged by 187.36% to 18210000.0 in 2023, then slumped by 57110.74% to 10418075000.0 in 2024, then soared by 99.73% to 28199988.0 in 2025.
- Business Quant data shows BNTC's Income from Continuing Operations at 28199988.0 in Q4 2025, 17378369000.0 in Q3 2025, and 10190000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Benitec Biopharma | 530.96 Mn | 530.96 Mn | - | -28.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.20 Mn |
| Sep 30, 2025 | -17.38 Bn |
| Jun 30, 2025 | -10.19 Mn |
| Mar 31, 2025 | -12.18 Bn |
| Dec 31, 2024 | -10.42 Bn |
| Sep 30, 2024 | -4.86 Bn |
| Jun 30, 2024 | -2.35 Bn |
| Mar 31, 2024 | -357.43 Mn |
| Dec 31, 2023 | -18.21 Mn |
| Sep 30, 2023 | -6.22 Mn |
| Jun 30, 2023 | -16.44 Mn |
| Mar 31, 2023 | -5.84 Mn |
| Dec 31, 2022 | -6.34 Mn |
| Sep 30, 2022 | -5.38 Mn |
| Jun 30, 2022 | -22.70 Mn |
| Mar 31, 2022 | -3.60 Mn |
| Dec 31, 2021 | -4.99 Mn |
| Sep 30, 2021 | -5.05 Mn |
| Jun 30, 2021 | -4.05 Mn |
| Mar 31, 2021 | -3.80 Mn |